Under a tenth of individuals who could benefit from obesity jabs including Wegovy are able to get them, warns the WHO as it releases its first advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for increased and just availability to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The new guidelines recognises that excess weight is a lifelong illness that can be treated with comprehensive and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major hurdles to widespread availability to the treatments that can help people shift substantial body mass, says the agency.
Weight-Loss Drug Supply Crisis
Even in the current most favorable outlook, the production of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The recommendation encourages nations and manufacturers to increase access, via measures such as patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Work
The injections replicate a body's own hormone to slow digestion, reduce hunger and increase the sense of being full so users eat less.
People usually begin shedding pounds after several weeks of commencing the weekly injections.
Studies indicates users may regain a significant portion a year later of halting the drug, because their normal appetite resume.
To be overweight or obese elevates your chance for developing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity impacts individuals in every country and was associated with millions of deaths worldwide in 2024, as per the WHO.
